[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperbaric-oxygen-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperbaric-oxygen-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100603721","hyperbaric-oxygen-therapy-to-improve-autologous-fat-graft-intake-in-irradiated-breast-100603721",false,"NCT07140198","Hyperbaric Oxygen Therapy to Improve Autologous Fat Graft Intake in Irradiated Breast","Prospective Study to Evaluate the Effectiveness of Hyperbaric Oxygen Therapy (HBOT) to Increase the Survival of Autologous Fat Transfer for Breast Reconstruction After Radiotherapy: A Randomized Controlled Phase II Cross-over Trial","Inclusion Criteria:\n\n* Adult (18 y.o. or more) female patients considered for lipofilling following breast reconstruction in an oncological setting which received radiation therapy on the affected breast.\n* Ability to provide informed consent, documented by signature\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Unability to provide informed consent\n* Previous enrolment into the current investigation\n\nContra-indication to HBOT :\n\n* Anamnestically reported spontaneous pneumothorax\n* Status post-thoracotomy\n* Significant intra-pulmonary lesions (including emphysematous bullae)\n* Respiratory function disorders (both obstructive and restrictive syndromes)\n* Pregnancy\n* Major psychiatric disorders\n* Uncontrollable claustrophobic reaction\n* Seizures, even if treated and asymptomatic for some time\n* Status post-severe traumatic brain injury with neurological deficits and seizures\n* Decompensated heart failure\n* Recent myocardial infarction (\\\u003C6 months) or with persistent hemodynamic sequelae\n* Spastic coronary angina\n* Cardiac arrhythmias, atrioventricular block, Wolff-Parkinson-White syndrome, sinus node dysfunction, Lown-Ganong-Levine syndrome\n* Cardiac pacemakers with unknown pressure resistance\n* Severe bradycardia\n* Sinus ostium displacement (acute or chronic)\n* Displacement of the auditory canal entrance (acute or chronic)\n* Status post-tympanoplasty type I-III \\\u003C3 months\n* Acute febrile state\n* Optic neuritis\n* Unstabilized hyperthyroidism\n\nContra-indication to MRI :\n\n* Non-MRI-compatible pacemaker, cochlear implant, drug-infusion pump or neurostimulator.\n* Metallic foreign body in critical area (eye, brain, etc.)\n* Ferromagnetic vascular surgical clips of older generation, e.g., for intracranial aneurysm repair.","FEMALE","18 Years",{"count":19,"type":20},16,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) enhances fat graft survival in lipofilling procedures in irradiated breast cancer patients. The main questions it aims to answer are:\n\nDoes it improve fat graft survival ? Evaluate safety and tolerability of HBOT in this setting? Researchers will compare patient receiving HBOT to a control group without HBOT to see if.\n\nSixteen female patients will undergo two autologous fat grafting sessions: one with HBOT and one without, in a randomized sequence. Patients will undergo three MRI during the study to evaluate the fat retention rate.",[26,27,28],"Breast Reconstruction","Lipofilling","Hyperbaric Oxygen Therapy",[30,31,32,33],"breast reconstruction","Irradiation","hyperbaric oxygen therapy","lipofilling","RECRUITING","2026-05-11",{"date":37,"type":38},"2026-05-14","ACTUAL",{"date":40,"type":38},"2026-03-01",{"date":42,"type":20},"2028-12",{"name":44,"class":45},"University Hospital, Geneva","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":46},"100579046","effect-of-hyperbaric-oxygen-therapyhbot-on-patients-with-sudden-sensorineural-hearing-lossssnhl-and-coagulation-function-100579046","NCT06819202","Effect of Hyperbaric Oxygen Therapy(HBOT) on Patients With Sudden Sensorineural Hearing Loss(SSNHL) and Coagulation Function","Effect of Hyperbaric Oxygen Therapy on Patients With Sudden Sensorineural Hearing Loss and Coagulation Function","Inclusion Criteria:\n\n* Meet the diagnostic criteria for sudden deafness in the American Academy of Otolaryngology Head and Neck Surgery 2019 Clinical Practice Guidelines for Sudden Deafness;\n* Aged 18-75 years old;\n* Patients with unilateral sudden deafness for the first time, and the onset time is less than 2 weeks.\n\nExclusion Criteria:\n\n* Patients with other ear diseases, such as auditory trauma, barotrauma, retrocochlear disease, bilateral hearing loss, history of chronic otitis media in the same ear, and history of surgery in the same ear;\n* Patients with serious primary diseases such as heart, liver, kidney dysfunction and hematopoietic system diseases;\n* Pregnant and nursing patients;\n* Accompanied by serious mental illness;\n* Patients with incomplete clinical data.","ALL","75 Years",{"count":57,"type":20},1309,"OBSERVATIONAL","The objective of this observational study was to understand the effect of HBO on patients with SSNHL and its association with coagulation function and prognosis.\n\nThe main question it aims to answer is whether HBO therapy can improve outcomes and coagulation function in patients with SSNHL.\n\nThe prognosis of SSNHL patients receiving HBO and SSNHL patients not receiving HBO were compared",[61,28],"Sudden Sensorineural Hearing Loss (SSNHL)","NOT_YET_RECRUITING","2025-05-13",{"date":65,"type":38},"2025-05-14",{"date":67,"type":20},"2025-06-01",{"date":69,"type":20},"2025-12-01",{"name":71,"class":45},"Sun Yuting",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":55,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100514568","cognitive-improvement-after-carotid-stenting-in-hyperbaric-oxygen-therapy-trial-100514568","NCT05980195","Cognitive Improvement After Carotid Stenting in Hyperbaric Oxygen Therapy Trial","Cognitive Improvement After cARotid stEnting in HyperBaric Oxygen Therapy Trial (CARE-HBOT)","Inclusion Criteria:\n\n1. Age from 18 to 75 years\n2. National Institute of Health stroke scale (NIHSS) ≤3\n3. Culprit vessel was the common carotid artery or extracranial internal carotid artery, involving or not involving the external carotid artery\n4. The degree of culprit arterial stenosis is 70-99 % ; based on Digital subtraction angiography (DSA) (According to North American Symptomatic Carotid Endarterectomy Trial (NASCET) method)\n5. The diameter of the target vessel between 4.0 mm - 9.0 mm\n6. Mini-mental State Examination (MMSE) score : education level-middle school ≤ 24; education level-high school ≤ 20 ; education level-college ≤ 17\n7. Baseline modified Rankin Scale (mRS) score ≤ 3\n8. Patient understands the purpose and requirements of the study, and has provided informed consent\n\nExclusion Criteria:\n\n1. Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion\n2. Serious perioperative complications affecting subsequent hyperbaric oxygen therapy (such as cerebral hemorrhage, disabling stroke, etc.)\n3. Any history of brain parenchymal or subarachnoid, subdural or extradural haemorrhage in the past 12 months\n4. Hemorrhagic transformation after ischemic stroke within 60 days before enrollment\n5. Intracranial artery stenosis caused by non-atherosclerotic lesions, including: arterial dissection, Moyamoya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any other intracranial infections, any intracranial stenosis related to cerebrospinal fluid cells, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, postpartum vascular disease, suspected vasospasm, suspicious embolism recanalization, etc\n6. Nervous system diseases in the past two years, characterized by transient or fixed neurological deficits (such as partial or secondary generalized seizures of epilepsy, complex or classic migraine, tumor or other intracranial space-occupying lesions, subdural hematoma, brain contusion or other post-traumatic lesions, intracranial infection, demyelinating diseases, intracranial hemorrhage, etc.), which cannot be distinguished from cerebral infarction\n7. History of stenting of an intracranial or extracranial artery\n8. Presence of any unequivocal cardiac source of embolism\n9. Chronic atrial fibrillation; paroxysmal atrial fibrillation or paroxysmal atrial fibrillation in the past 6 months, or a history of paroxysmal atrial fibrillation, requiring long-term anticoagulation\n10. Myocardial infarction in the past 30 days\n11. Combined with intracranial tumor, aneurysm or intracranial arteriovenous malformation\n12. Cannot tolerate dual antiplatelet therapy due to known diseases (such as gastrointestinal bleeding)\n13. Contraindications to heparin, aspirin, clopidogrel, ticagrelor, anesthesia, or contrast agents\n14. Hemoglobin\\\u003C100g\u002FL, platelet count \\\u003C100×109\u002FL, international normalized ratio (INR)\\>1.5, or heparin-related thrombocytopenia or uncorrectable factors leading to bleeding\n15. Not suitable for vessel angiography or endovascular interventional therapy (such as morbid obesity; serious vascular tortuosity that hinders the safe introduction of the guiding catheter)\n16. Severe hepatic and renal dysfunction\n17. Major surgery within the past 30 days or planned within 90 days\n18. Renal artery, iliac artery, and coronary artery requiring simultaneous intervention\n19. Life expectancy \\\u003C1 year\n20. Pregnant or lactating women\n21. Cognitive assessment and follow-up could not be completed due to factors such as severe aphasia, neuropsychological illness or mental illness or dysarthria and inability to communicate\n22. History of drug or alcohol abuse, head trauma or central nervous system infection; current use of drugs that affect cognition\n23. Combined with diseases that are not suitable for hyperbaric oxygen therapy (such as untreated pneumothorax, uncontrolled epilepsy, claustrophobia, angle-closure glaucoma, cavitary pulmonary tuberculosis, etc.)\n24. Enrollment in another study that would conflict with the current study",{"count":80,"type":20},90,[23],"The purpose of CARE-HBOT study is to evaluate whether patients with symptomatic severe carotid artery stenosis with cognitive impairment who underwent hyperbaric oxygen therapy plus standard medical treatment after stent implantation could improve their cognitive function compared with those who underwent standard postoperative medical treatment.",[84,85,28,86],"Carotid Stenosis","Cognitive Impairment","Stent Implantation","2024-07-17",{"date":89,"type":38},"2024-07-18",{"date":91,"type":20},"2024-07-16",{"date":93,"type":20},"2025-12-31",{"name":95,"class":45},"Beijing Tiantan Hospital"]